Skip to main content

Table 4 Subgroup analysis based on the route of administration and the study quality

From: Efficacy and safety of tranexamic acid usage in patients undergoing posterior lumbar fusion: a meta-analysis

Outcomes

Subgroup

Study (N)

RR/WMD

95%CI

I2 (%)

P

Total blood loss

IV TXA

4

-287.25

(−411.81,-162.70)

79

<0.001

tTXA

1

− 283

(− 394.09,-171.91)

–

<0.001

Combined

1

− 165

(− 220.77,-109.23)

–

<0.001

Intraoperative blood loss

IV TXA

6

−82.73

(−122.80,-42.66)

48

<0.001

tTXA

2

−17.25

(−63.51,29.00)

0

0.46

Combined

1

− 102

(− 130.87,-73.13)

–

<0.001

Postoperative blood loss

IV TXA

6

−135.66

(−164.24,-107.08)

84

<0.001

tTXA

2

−119.17

(−210.40,-27.94)

71

<0.001

Combined

1

−118

(− 131.66,-104.34)

–

<0.001

Postoperative 24 h HB decline

IV TXA

5

−0.28

(−0.42,-0.14)

32

<0.001

tTXA

1

−0.2

(−1.03,0.63)

–

0.64

Combined

1

−0.7

(−1.20,-0.2)

–

0.006

Total blood loss

High

4

− 208.93

(− 286.07,-131.78)

42

<0.001

Moderate

1

−165.00

(−220.77,-109.23)

–

<0.001

Intraoperative blood loss

High

4

−64.12

(−108.32,-19.91)

31

0.004

Moderate

2

−70.73

(−150.56,9.11)

68

0.08

Postoperative blood loss

High

4

−128.51

(−153.93,-103.08)

83

<0.001

Moderate

2

−128.52

(− 173.86,-83.18)

32

<0.001

Postoperative 24 h HB decline

High

3

−0.23

(−0.39,-0.08)

23

0.003

Moderate

2

−0.57

(−0.99,-0.14)

3

0.009

  1. IV: intravenous use of TXA; tTXA: topical use of TXA; Combined: combined IV administration and topical application of TXA; −: no available; High: high quality; Moderate: moderate quality
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us